JR-141
Phase 3Recruiting 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis II
Conditions
Mucopolysaccharidosis II
Trial Timeline
Feb 22, 2023 โ Feb 28, 2028
NCT ID
NCT05594992About JR-141
JR-141 is a phase 3 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis II. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05594992. Target conditions include Mucopolysaccharidosis II.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05594992 | Phase 3 | Recruiting |
| NCT04348136 | Phase 2/3 | Active |
| NCT03708965 | Phase 2 | Active |
| NCT03568175 | Phase 2/3 | Completed |
| NCT03128593 | Phase 1/2 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis II